Drugs / Metformin XR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01525225 | Sep 2012 → Jun 2013 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT01305551 | Mar 2011 | type 2 diabetes mellitus | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01999686 | Oct 2014 → Feb 2019 | polycystic ovary syndrome | Dexa Medica Group | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT04047940 Comparator | Nov 2019 → Feb 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02738879 Background | May 2016 → Jan 2018 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01606007 Background | Jul 2012 → Jan 2014 | type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT01434186 Background | May 2012 → Apr 2016 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00859898 Comparator | Apr 2009 → May 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metformin XR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04047940 ↗ |
| Modality | Small molecule | — CHEMBL1187231 ↗ |
| Route | Oral | “Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks” NCT00859898 ↗ |